Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients

Authors

  • Zhenhua Du Department of Obstetrics and Gynecology, Sheng Jing Hospital of China Medical University, Shenyang, Liaoning 110022
  • Xiaolin Ma Department of Obstetrics and Gynecology, Sheng Jing Hospital of China Medical University, Shenyang, Liaoning 110022

DOI:

https://doi.org/10.3329/bjp.v10i3.23079

Keywords:

Carboplatin, Ovarian cancer, Paclitaxel, Randomized clinical trial

Abstract

We investigated dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment on stage II-IV ovarian cancer patients. Between July, 2011, and October, 2014, a total of 221 patients was randomly assigned to receive dose-dense weekly paclitaxel and carboplatin group (n = 109) and conventional paclitaxel and carboplatin group (n = 112), just after the sixth chemotherapy cycles, and at 12 months after randomization. Median progression-free survival (PFS) was 16.8 months (range 3.3-48+ months) of conventional paclitaxel and carboplatin group was lower than that of dose-dense weekly paclitaxel and carboplatin group 27.6 months (range 4.2-51+ months). But, these clinical responses were not statistical significance in each group. In conclusion, dose-dense weekly paclitaxel and carboplatin treatment improves survival compared with conventional paclitaxel and carboplatin treatment. 

Downloads

Download data is not yet available.
Abstract
1210
Download
1136 Read
452

References

Burris HA, 3rd, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012; 11: 1820-28.

Chen D, Cheng J, Yang K, Ma Y, Yang F. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Onco Targets Ther. 2013; 6: 1507-14.

Chen K, Wei H, Ling S, Yi C. Expression and significance of transforming growth factor-beta1 in epithelial ovarian cancer and its extracellular matrix. Oncol Lett. 2014; 8: 2171-74.

Harano K, Terauchi F, Katsumata N, Takahashi F, Yasuda M, Takakura S, Takano M, Yamamoto Y, Sugiyama T. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Ann Oncol. 2014; 25: 251-57.

Inoue A, Usui K, Ishimoto O, Matsubara N, Tanaka M, Kanbe M, Gomi K, Koinumaru S, Saijo Y, Nukiwa T. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer. 2006; 52: 83-87.

Januchowski R, Zawierucha P, Rucinski M, Zabel M. Microarray-based detection and expression analysis of extracellular matrix proteins in drugresistant ovarian cancer cell lines. Oncol Rep. 2014; 32: 1981-90.

Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013; 14: 1020-26.

Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374: 1331-38.

Kumagai S, Sugiyama T, Shoji T, Michimae H, Katsumata N, Aoki D, Terauchi F, Jobo T, Ochiai K, Yasuda M. Does severe anemia caused by dose-dense paclitaxel-carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese Gynecologic Oncology Group 3016 trial. Int J Gynecol Cancer. 2011; 21: 1585-91.

Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Down-regulation of NEK11 is associated with drug resistance in ovarian cancer. Int J Oncol. 2014; 45: 1266-74.

Mundhenke C, Weigel MT, Sturner KH, Roesel F, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Hilpert F, Jonat W, Maass N. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with paclitaxel and carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol. 2008; 134: 1397-405.

Numazaki R, Miyagi E, Onose R, Nakazawa T, Sugiura K, Asukai K, Nakayama H, Miyamatsu A, Okamoto N, Hirahara F. Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer. Int J Clin Oncol. 2006; 11: 221-28.

Pu Z, Yuan X, Zhang X, Chen Q, Xie H. Meta-analysis on the association between CYP2D6*10 gene polymorphism and disease free survival of breast cancer patients receiving tamoxifen treatment in Asia. Bangladesh J Pharmacol. 2014; 9: 652-62.

Robinson WR, Davis N, Rogers AS. Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2008; 18: 891-95.

Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med. 2006; 79: 153-63.

Xie Y, Peng Z, Shi M, Ji M, Guo H, Shi H. Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin resistant ovarian cancer. Mol Med Rep. 2014; 10: 2346-50.

Additional Files

Published

2015-07-01

How to Cite

Du, Z., and X. Ma. “Dose-Dense Weekly Paclitaxel and Carboplatin Compared With Conventional Paclitaxel and Carboplatin Treatment for Stage II-IV Ovarian Cancer Patients”. Bangladesh Journal of Pharmacology, vol. 10, no. 3, July 2015, pp. 489-93, doi:10.3329/bjp.v10i3.23079.

Issue

Section

Clinical Trial